2-[3-(3-chlorophenyl)-7-(2,9-diazaspiro[5.5]undec-2-yl)-1-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-(1-methylethyl)acetamide | 1192687-93-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 2-[3-(3-chlorophenyl)-7-(2,9-diazaspiro[5.5]undec-2-yl)-1-oxopyrrolo[1,2-a]pyrazin-2(1H)-yl]-N-(1-methylethyl)acetamide
• 英文别名: 2-[3-(3-chlorophenyl)-7-(2,9-diazaspiro[5.5]undecan-2-yl)-1-oxopyrrolo[1,2-a]pyrazin-2-yl]-N-propan-2-ylacetamide
• CAS: 1192687-93-6
• 化学式: C₂₇H₃₄ClN₅O₂
• 分子量: 496.052
• InChiKey: RDQVDPDAWJYHQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] PYRROLO [1, 2-A] PYRAZINE DERIVATIVES AS VASOPRESSIN VIB RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRROLO [1, 2-A] PYRAZINE ANTAGONISTES DES RÉCEPTEURS V1B DE LA VASOPRESSINE
  申请人：GLAXO GROUP LTD

  公开号：WO2009130231A1

  公开（公告）日：2009-10-29

  The present invention relates to novel compounds of formula (I) or salts thereof; wherein R is -X-[CH2]nCR4R5-Y; or a group G; R1 is H or C1 -C4 alkyl; R2 is aryl, heteroaryl or C3-C7 cycloalkyl, which may be substituted with one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, - CN; R3 is -CH2-C(=O)-NH-R6; X is -CR7R8-, -O-, -NR9-, -S-; Y is-NR10R11 R4 is H or C1 -C4 alkyl; R5 is H or C1 -C4 alkyl; R6 is C1-C6 alkyl, C3-C6 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R7 is H or C1 -C4 alkyl; R8 is H or C1 -C4 alkyl; R9 is H or C1 -C4 alkyl; R10 is H or C1-C4 alkyl, or together with R11 forms a 4-8 saturated or unsaturated heterocycle ring which may comprise a further heteroatom selected from O, S and -NR12; such heterocycle may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R11 is H or C1 -C4 alkyl; R12 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; G is one of the groups selected from the list consisting of G1, G2, G3, G4, G5, G6, G7, G8, G9, G10, G11 and G12; R 13 is H or C1-C4 alkyl, or together with R14 forms a 4-8 saturated or unsaturated heterocycle ring which may comprise a further heteroatom selected from O, S and -NR24; such heterocycle may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R14 R16 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R15, R 17 correspond to H or C1-C4 alkyl and may assume different meanings; R 18 is H or C1-C4 alkyl, or together with R17 forms a 4-8 saturated or unsaturated heterocycle ring which may comprise a further heteroatom selected from O, S and -NR25; such heterocycle may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R19, R20, R21, R22, R23, R24, R25 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; R26, R27, R28, R29 is H, C1-C6 alkyl, C3-C7 cycloalkyl; C3-C6 cycloalkyl- (C1 -C2 alkyl); which may be substituted by one or more halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy; I, I' correspond to 1 or 2 and may assume different meanings; m, m', m", m"', mιv, mv correspond to 0, 1 or 2 and may assume different meanings; n is 1, 2 or 3; q is 1, 2 or 3; p, p', p", p'" correspond to 0, 1, 2 or 3 and may assume different meanings; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as antagonists of V1b receptors, e.g. to treat depression and anxiety.

  本发明涉及以下式（I）的新化合物或其盐；其中R为-X-[ ]nCR4R5-Y；或者为基团G；R1为H或C1-C4烷基；R2为芳基、杂环芳基或C3-C7环烷基，可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R3为-CH2-C（=O）-NH-R6；X为-CR7R8-、-O-、-NR9-、-S-；Y为-NR10R11；R4为H或C1-C4烷基；R5为H或C1-C4烷基；R6为C1-C6烷基、C3-C6环烷基；C3-C6环烷基-（C1-C2烷基）；可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R7为H或C1-C4烷基；R8为H或C1-C4烷基；R9为H或C1-C4烷基；R10为H或C1-C4烷基，或者与R11一起形成一个含有O、S和-NR12等进一步杂原子的4-8饱和或不饱和杂环环；该杂环可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R11为H或C1-C4烷基；R12为H、C1-C6烷基、C3-C7环烷基；C3-C6环烷基-（C1-C2烷基）；可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；G为从G1、G2、G3、G4、G5、G6、G7、G8、G9、G10、G11和G12的列表中选择的一种基团；R13为H或C1-C4烷基，或者与R14一起形成一个含有O、S和-NR24等进一步杂原子的4-8饱和或不饱和杂环环；该杂环可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R14 R16为H、C1-C6烷基、C3-C7环烷基；C3-C6环烷基-（C1-C2烷基）；可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R15、R17对应于H或C1-C4烷基，可能具有不同的含义；R18为H或C1-C4烷基，或者与R17一起形成一个含有O、S和-NR25等进一步杂原子的4-8饱和或不饱和杂环环；该杂环可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R19、R20、R21、R22、R23、R24、R25为H、C1-C6烷基、C3-C7环烷基；C3-C6环烷基-（C1-C2烷基）；可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；R26、R27、R28、R29为H、C1-C6烷基、C3-C7环烷基；C3-C6环烷基-（C1-C2烷基）；可以被一个或多个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基取代；I、I'对应于1或2，可能具有不同的含义；m、m'、m"、m"'、mιv、mv对应于0、1或2，可能具有不同的含义；n为1、2或3；q为1、2或3；p、p'、p"、p"'对应于0、1、2或3，可能具有不同的含义；它们的制备方法、在这些方法中使用的中间体、含有它们的药物组合物以及它们作为V1b受体拮抗剂在治疗中的用途，例如用于治疗抑郁症和焦虑症。